| PARP inhibitors: A new era of targeted therapy S Tangutoori, P Baldwin, S Sridhar Maturitas 81 (1), 5-9, 2015 | 169 | 2015 |
| A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice D Zhang, P Baldwin, AS Leal, S Carapellucci, S Sridhar, KT Liby Theranostics 9 (21), 6224, 2019 | 47 | 2019 |
| Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation AL van de Ven, S Tangutoori, P Baldwin, J Qiao, C Gharagouzloo, ... Molecular cancer therapeutics 16 (7), 1279-1289, 2017 | 47 | 2017 |
| Sustained release talazoparib implants for localized treatment of BRCA1-deficient breast cancer JE Belz, R Kumar, P Baldwin, NC Ojo, AS Leal, DB Royce, D Zhang, ... Theranostics 7 (17), 4340, 2017 | 30 | 2017 |
| Nanoformulation of talazoparib increases maximum tolerated doses in combination with temozolomide for treatment of Ewing sarcoma P Baldwin, R Likhotvorik, N Baig, J Cropper, R Carlson, R Kurmasheva, ... Frontiers in Oncology 9, 1416, 2019 | 26 | 2019 |
| Nanoformulation of talazoparib delays tumor progression and ascites formation in a late stage cancer model P Baldwin, AW Ohman, JE Medina, ET McCarthy, DM Dinulescu, ... Frontiers in oncology 9, 353, 2019 | 19 | 2019 |
| Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment P Baldwin, AW Ohman, S Tangutoori, DM Dinulescu, S Sridhar International Journal of Nanomedicine, 8063-8074, 2018 | 15 | 2018 |
| Quantification of cellular drug biodistribution addresses challenges in evaluating in vitro and in vivo encapsulated drug delivery CB Rodell, P Baldwin, B Fernandez, R Weissleder, S Sridhar, JM Dubach Advanced therapeutics 4 (3), 2000125, 2021 | 6 | 2021 |
| Respiratory control in liver mitochondria of rats hosting the Walker 256 carcinoma tumor PE Baldwin, DT George, CC Cunningham Experientia 31, 1333-1334, 1975 | 6 | 1975 |
| In vitro analysis of PARP inhibitor nanoformulations P Baldwin, S Tangutoori, S Sridhar International Journal of Nanomedicine 13 (sup1), 59-61, 2018 | 5 | 2018 |
| Generation of dose–response curves and improved ic50s for parp inhibitor nanoformulations P Baldwin, S Tangutoori, S Sridhar Cancer Nanotechnology: Methods and Protocols, 337-342, 2017 | 3 | 2017 |
| Nanoformulation of the PARP inhibitor olaparib enables radiosensitization of a radiation-resistant prostate cancer model P Baldwin, AL Van De Ven, N Seitzer, S Clohessy, RA Cormack, ... International Journal of Radiation Oncology, Biology, Physics 96 (2), E595, 2016 | 2 | 2016 |
| Nanoformulations of PARP inhibitors Olaparib and Talazoparib for targeted cancer therapy P Baldwin, A Ohman, J Thong, S Tangutoori, A van de Ven, R Kumar, ... Cancer Research 76 (14_Supplement), 4335-4335, 2016 | 2 | 2016 |
| Nanoencapsulated combination drug formulations P Baldwin, S Sridhar, B Singh US Patent 11,648,211, 2023 | 1 | 2023 |
| Abstract LB105: In vivo CAR T therapy: targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication A Emmanuel, P Cruite, H Ennajdaoui, C Passaro, P Baldwin, V Duback, ... Cancer Research 81 (13_Supplement), LB105-LB105, 2021 | 1 | 2021 |
| Combination nanotherapy using the PARP inhibitor talazoparib and cyclin dependent kinase inhibitor dinaciclib P Baldwin, A Orriols, S Sridhar Cancer Research 79 (13_Supplement), 3642-3642, 2019 | 1 | 2019 |
| Nanoformulated Talazoparib enhances the efficacy and reduces the toxicity of this PARP inhibitor in a preclinical model of BRCA‐deficient breast cancer D Zhang, P Baldwin, S Sridhar, K Liby The FASEB Journal 32, 565.10-565.10, 2018 | 1 | 2018 |
| Abstract B30: sustained release of PARP inhibitor talazoparib and chemotherapeutic docetaxel from modified brachytherapy spacers for treatment of breast and prostate cancer J Belz, NC Ojo, P Baldwin, R Kumar, A Ven, K Liby, R Cormack, ... Cancer Research 77 (2_Supplement), B30-B30, 2017 | 1 | 2017 |
| Abstract B48: Prostate cancer pre-treatment with nanoformulated Olaparib overcomes radiation resistance AL Ven, S Tangutoori, P Baldwin, J Qiao, C Gharagouzloo, N Seitzer, ... Cancer Research 77 (2_Supplement), B48-B48, 2017 | 1 | 2017 |
| Prostate cancer pre-treatment with nanoformulated olaparib overcomes radiation resistance AL van de Ven, S Tangutoori, P Baldwin, J Qiao, C Gharagouzloo, ... CANCER RESEARCH 77, 2017 | 1 | 2017 |
